247 related articles for article (PubMed ID: 31748121)
21. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients.
Hall PS; Harshman LC; Srinivas S; Witteles RM
JACC Heart Fail; 2013 Feb; 1(1):72-8. PubMed ID: 24621801
[TBL] [Abstract][Full Text] [Related]
22. Cardiotoxicities of 5-Fluorouracil and Other Fluoropyrimidines.
Shiga T; Hiraide M
Curr Treat Options Oncol; 2020 Mar; 21(4):27. PubMed ID: 32266582
[TBL] [Abstract][Full Text] [Related]
23. State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: a literature review.
Berardi R; Caramanti M; Savini A; Chiorrini S; Pierantoni C; Onofri A; Ballatore Z; De Lisa M; Mazzanti P; Cascinu S
Crit Rev Oncol Hematol; 2013 Oct; 88(1):75-86. PubMed ID: 23522920
[TBL] [Abstract][Full Text] [Related]
24. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management.
Curigliano G; Cardinale D; Dent S; Criscitiello C; Aseyev O; Lenihan D; Cipolla CM
CA Cancer J Clin; 2016 Jul; 66(4):309-25. PubMed ID: 26919165
[TBL] [Abstract][Full Text] [Related]
25. Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system.
Babiker HM; McBride A; Newton M; Boehmer LM; Drucker AG; Gowan M; Cassagnol M; Camenisch TD; Anwer F; Hollands JM
Crit Rev Oncol Hematol; 2018 Jun; 126():186-200. PubMed ID: 29759560
[TBL] [Abstract][Full Text] [Related]
26. Cardiovascular Complications Associated with Multiple Myeloma Therapies: Incidence, Pathophysiology, and Management.
Patel VG; Cornell RF
Curr Oncol Rep; 2019 Mar; 21(4):29. PubMed ID: 30834998
[TBL] [Abstract][Full Text] [Related]
27. Cardio-oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients.
Tajiri K; Aonuma K; Sekine I
Jpn J Clin Oncol; 2017 Aug; 47(8):678-682. PubMed ID: 28505345
[TBL] [Abstract][Full Text] [Related]
28. Unanticipated Cardiotoxicity Associated with Targeted Anticancer Therapy in Patients with Hematologic Malignancies Patients: Natural History and Risk Factors.
Shah C; Gong Y; Szady A; Sun Q; Pepine CJ; Langaee T; Lucas AR; Moreb JS
Cardiovasc Toxicol; 2018 Apr; 18(2):184-191. PubMed ID: 29022233
[TBL] [Abstract][Full Text] [Related]
29. Curing Cancer, Saving the Heart: A Challenge That Cardioncology Should Not Miss.
Cardinale D; Biasillo G; Cipolla CM
Curr Cardiol Rep; 2016 Jun; 18(6):51. PubMed ID: 27108361
[TBL] [Abstract][Full Text] [Related]
30. The prevention and management of cardiovascular complications of chemotherapy in patients with cancer.
Youssef G; Links M
Am J Cardiovasc Drugs; 2005; 5(4):233-43. PubMed ID: 15984906
[TBL] [Abstract][Full Text] [Related]
31. Cancer Therapeutics-Related Cardiovascular Complications. Mechanisms, Diagnosis and Treatment.
Oikonomou E; Anastasiou Μ; Siasos G; Androulakis E; Psyrri A; Toutouzas K; Tousoulis D
Curr Pharm Des; 2018; 24(37):4424-4435. PubMed ID: 30636595
[TBL] [Abstract][Full Text] [Related]
32. Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology.
Raschi E; De Ponti F
Intern Emerg Med; 2012 Apr; 7(2):113-31. PubMed ID: 22161318
[TBL] [Abstract][Full Text] [Related]
33. Cardio-oncology: cardiovascular complications of cancer therapy.
Henning RJ; Harbison RD
Future Cardiol; 2017 Jul; 13(4):379-396. PubMed ID: 28660778
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological foundations of cardio-oncology.
Minotti G; Salvatorelli E; Menna P
J Pharmacol Exp Ther; 2010 Jul; 334(1):2-8. PubMed ID: 20335321
[TBL] [Abstract][Full Text] [Related]
35. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Zambelli A; Della Porta MG; Eleuteri E; De Giuli L; Catalano O; Tondini C; Riccardi A
Breast; 2011 Apr; 20(2):176-83. PubMed ID: 21146409
[TBL] [Abstract][Full Text] [Related]
36. Chemotherapy-induced cardiovascular toxicity: beyond anthracyclines.
Ai D; Banchs J; Owusu-Agyemang P; Cata JP
Minerva Anestesiol; 2014 May; 80(5):586-94. PubMed ID: 24122036
[TBL] [Abstract][Full Text] [Related]
37. Building a Cardio-Onco-Hematology Program.
Herrmann J; Loprinzi C; Ruddy K
Curr Oncol Rep; 2018 Sep; 20(10):81. PubMed ID: 30203261
[TBL] [Abstract][Full Text] [Related]
38. Cardiovascular toxic effects of targeted cancer therapy.
Tajiri K; Aonuma K; Sekine I
Jpn J Clin Oncol; 2017 Sep; 47(9):779-785. PubMed ID: 28531278
[TBL] [Abstract][Full Text] [Related]
39. Optimizing cardio-oncology programs for cancer patients.
Francis SA; Asnani A; Neilan T; Scherrer-Crosbie M
Future Oncol; 2015; 11(14):2011-5. PubMed ID: 26198828
[No Abstract] [Full Text] [Related]
40. Rationale and design of the multidisciplinary team IntervenTion in cArdio-oNcology study (TITAN).
Pituskin E; Haykowsky M; McNeely M; Mackey J; Chua N; Paterson I
BMC Cancer; 2016 Sep; 16(1):733. PubMed ID: 27629548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
